Neuren Pharmaceuticals Annual Report 2017

ANNUAL REPORT Neuren Pharmaceuticals is a biopharmaceutical company developing new therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Incorporated in New Zealand and based in Melbourne, Australia, Neuren is listed on the ASX under the code NEU. The Board of Directors is pleased to present the Annual Report of Neuren Pharmaceuticals Limited for the year ended 31 December 2017, authorised on 8 May 2018. For, and on behalf of, the Board Dr Richard Treagus Dr Trevor Scott Chairman Director Statistically significant and clinically meaningful improvement demonstrated in Phase 2 clinical trial in girls with Rett syndrome aged 5 to 15 Agreement reached at End of Phase 2 Meeting with the US Food and Drug Administration on the key elements of the Phase 3 program for Rett syndrome Financing completed to continue critical manufacturing and non-clinical activities in preparation for Phase 3 New patents extending to 2032 granted in the United States, Europe and Japan covering trofinetide in Rett syndrome, Fragile X syndrome and other autism spectrum disorders KEY ACHIEVEMENTS